Fig. 4.

CP110 protein stability assays done independently in human (H522) and murine (ED-1) lung cancer cells that respectively had or not a KRAS mutation introduced. Empty vector or KRAS stably transfected (A) ED-1 and (B) H522 cells were transfected with the CP110-WT expression vector. Twenty-four hours later, cells were treated with or without cycloheximide (CHX, 40μg/ml) for the indicated time periods. Expression of CP110 protein at each time point was shown using immunoblot analyses and ImageJ quantification. Experiments were independently replicated at least three times. Quantifications by ImageJ were achieved by pooling independent experimental results.